Chryseobacterium indologenes central nervous system infection in infancy: an emergent pathogen? 2014

P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
Department of Paediatric Infectious Diseases and Immunodeficiency, Hospital Infantil Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013, Seville, Spain.

The isolation of Chryseobacterium indologenes as a causative micro-organism in human diseases is rare. Risk factors for infections caused by this pathogen include very young and very old age, indwelling devices, immune suppression and recent use of broad-spectrum antibiotics. Most cases suffer from bacteraemia or nosocomial pneumonia, whilst infection of the central nervous system (CNS) is extremely rare. We present a term-born infant diagnosed prenatally with holoprosencephaly and obstructive hydrocephalus, requiring post-natal ventriculoperitoneal shunt insertion. At 6 weeks of age, he suffered from Escherichia coli meningitis, showing satisfactory clinical response with antimicrobial therapy. Aged 11 months, he suffered from hyper-drainage syndrome, resulting in the removal of the shunt system. He represented 11 days post-operatively, with low-grade fever, irritability and cerebrospinal fluid (CSF) leakage. C. indologenes from CSF was isolated and antimicrobial therapy with ceftazidime and trimethoprim-sulfamethoxazole for 3 weeks resulted in good clinical response. This is the first documented community-acquired CNS infection due to C. indologenes in an infant without concomitant indwelling device or previous antibiotic pressure.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002494 Central Nervous System Infections Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process. CNS Infections,Central Nervous System Infection,Infections, Central Nervous System,CNS Infection,Infection, CNS,Infections, CNS
D002555 Cerebrospinal Fluid A watery fluid that is continuously produced in the CHOROID PLEXUS and circulates around the surface of the BRAIN; SPINAL CORD; and in the CEREBRAL VENTRICLES. Cerebro Spinal Fluid,Cerebro Spinal Fluids,Cerebrospinal Fluids,Fluid, Cerebro Spinal,Fluid, Cerebrospinal,Fluids, Cerebro Spinal,Fluids, Cerebrospinal,Spinal Fluid, Cerebro,Spinal Fluids, Cerebro
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015662 Trimethoprim, Sulfamethoxazole Drug Combination A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS. Trimethoprim-Sulfamethoxazole Combination,Abactrim,Bactifor,Bactrim,Biseptol,Biseptol-480,Centran,Centrin,Co-Trimoxazole,Cotrimoxazole,Drylin,Eslectin,Eusaprim,Insozalin,Kepinol,Kepinol Forte,Lescot,Metomide,Oriprim,Septra,Septrin,Sulfamethoxazole-Trimethoprim Combination,Sulprim,Sumetrolim,TMP SMX,TMP-SMX,Trimedin,Trimethoprim-Sulfamethoxazole,Trimethoprimsulfa,Trimezole,Trimosulfa,Biseptol 480,Biseptol480,Co Trimoxazole,Sulfamethoxazole Trimethoprim Combination,Trimethoprim Sulfamethoxazole,Trimethoprim Sulfamethoxazole Combination
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017714 Community-Acquired Infections Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility. Community Acquired Infection,Community-Acquired Infection,Infections, Community-Acquired,Acquired Infection, Community,Acquired Infections, Community,Community Acquired Infections,Infection, Community Acquired,Infection, Community-Acquired,Infections, Community Acquired

Related Publications

P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
April 2016, BMJ case reports,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
December 2008, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
January 2020, SAGE open medical case reports,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
March 2010, Revista Brasileira de terapia intensiva,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
January 2013, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
January 2012, Indian journal of medical microbiology,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
January 2014, Case reports in infectious diseases,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
June 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
February 2013, The Eurasian journal of medicine,
P Olbrich, and M Rivero-Garvía, and M D Falcón-Neyra, and J A Lepe, and J M Cisneros, and J Marquez-Rivas, and O Neth
July 2007, The Pediatric infectious disease journal,
Copied contents to your clipboard!